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ABSTRACT
Multidrug-resistant tuberculosis (MDR-TB) currently considers as the biggest issue and its subcategory, rifampicin-resistant TB (RR-TB). MDR-TB 
is defined as a resistant to isoniazid (H) and rifampicin (R), while the latter is resistant to rifampicin (R) only. Poorly controlled diabetes mellitus 
increases the risk of TB and leads to poor TB treatment outcomes as well it is consider potentially threating TB control. Difference in patients’ 
response and side effect developments toward anti-TB (ATB) medications requires rechallenging procedure that can be complicated at times. The 
management of MDR-TB can be complicated, especially, when the patient cannot tolerate the short regimen. Difference in patients’ response and side 
effect developments toward ATB medications requires rechallenging procedure which can have prolonged treatment time, hospital stay, and make 
patients exposed to hospital-acquired infection. This challenges and obstacles, however, could be prevented earlier by having strong DOTS strategy to 
prevent the development of resistance and reactivation of TB.
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INTRODUCTION
Tuberculosis (TB) is an infectious disease, highly contagious disease 
as well considering as a super major public health issue worldwide 
caused by a mycobacterium called Mycobacterium TB (MTB). According 
to the World Health Organization (WHO), in 2016, Malaysia reported 
an incidence and mortality of dying 5 per 1000 people. Following from 
2000, the mortality rate is decreasing steadily; however, the incidence 
of new and relapse cases is increasing.In 2016 alone, 370 cases in 
Malaysia are reported as MDR-/rifampicin-resistant (RR)-TB [1].
Type 2 diabetes mellitus (DM) currently has a very detrimental impact 
toward the health of Malaysians. It is defined as a condition where the 
pancreas does not produce enough insulin or the body’s cells do not react 
to insulin. National studies from 1996 to 2015 in Malaysia reported that 
the current prevalence in 2015 is 17.5%, over double since 1996. This 
huge increase was probably contributed by the doubling of the prevalence 
of undiagnosed DM. It is of serious concern that about half of the total 
reported DM is contributed by individuals with undiagnosed DM [2,3]. The 
WHO guideline has assigned MDR-TB short regimen and individualized 
treatment as the effective approach to cure the disease, by the usage of 
sensitivity tests and five different groups of drugs [4]. In addition, the 
management of DM in patient currently being treated with anti-TB (ATB) 
medications is based on efficiency and clinical experience due to many 
potential interfering factors between ATB and DM medications [5].
This report will present a patient with MDR-TB with underling DM 
who is currently receiving MDR-TB individual treatment and insulin 
regimen, respectively, for 36 days. Challenges in the management of 
these conditions are discussed.
CASE REPORT
A 47-year-old male Malay patient, with known medical history of 
RR-TB (pulmonary tuberculosis [PTB]) and uncontrolled DM, was 
referred to Institut Perubatan Respiratori (IPR) (Respiratory Medicine 
Institute) from a Hospital Kuala Lumpur. He was diagnosed with PTB 
and DM in May 2016. First-line ATB fixed-dose combination; Akurit-4 
(per tablet ethambutol HCl 275 mg, rifampicin 150 mg, isoniazid 75 
mg, and pyrazinamide 400 mg) and oral hypoglycaemic agents (OHA); 
metformin 1 g BD and gliclazide 80 mg BD. The regimen showed 
improvement as the patient coughs occasionally. However, he defaulted 
his TB regimen in 2016. A MTB culture and sensitivity test in May 2017 
evidenced rifampicin resistance and susceptibility to pyrazinamide (Z), 
streptomycin (S), and ethambutol (E).
On admission, the patient was well but reported to have hemoptysis, 
fever, night sweats, and consistent dry cough as initial symptoms. 
His blood glucose level was 24.1 mmol/L. The chest X-ray showed 
consolidation in the base of the left lung. Laboratory investigation 
showed low albumin level of 27.2 g/L. The MTB culture and sensitivity 
test evidenced a positive result. Based on patient’s history and 
current symptoms, MDR-TB short regimen and insulin therapy were 
immediately started on day 1 which are composed in Table 1.
The MDR-TB short regimen lasted for only 6 days when the patient 
started to develop nausea, vomiting, fever, and urticaria rash. The 
patient was given chlorpheniramine tablet 4 mg and loratadine tablet 
10 mg once daily. The short regimen was suspended for 7 days to prevent 
worsening of side effects. The patient was started on chlorpheniramine 
4 mg and loratadine 10 mg once daily, and betamethasone cream 1:4 
locally applied twice daily. As the patient had become intolerant to the 
short regimen, the individualized regimen was planned.
On the day 13, the patient was started on streptomycin (S) 250 mg once 
daily. The dose was increased to 500 mg and then 750 mg for the next 
2 days. Patient’s renal function was monitored to avoid nephrotoxicity. 
On day 17, levofloxacin (Lfx) 750 mg once daily rechallenge was started 
but then stopped 3 days later when the patient experienced swelling on 
his face. It was later diagnosed as secondary angioedema. The reaction 
resolved 3 days after the medication was stopped.
On the day 22, pyrazinamide (Z) 1500 mg once daily rechallenge was 
started, and the patient uric acid level was monitored for gout. On the 
day 27, ethambutol (E) was administered for rechallenge with daily 
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dosage increments of 400 mg, 800 mg, and 1200 mg for the next 3 days. 
On day 29, ethionamide (Eto) 750 mg once daily rechallenge was 
started. However, the next day, the patient complains of dizziness. His 
blood pressure also reduced from the usual day-to-day reading. Eto was 
withheld for 3 days before being stopped.
The latest MTB culture and sensitivity result obtained after 26 days 
of admission showed no improvement. Resistance to isoniazid and 
rifampicin was observed while amikacin, kanamycin, capreomycin, 
viomycin, and fluoroquinolones showed susceptibility. As per the last 
day, this patient was followed up (day 35), and he was started on high-
dose isoniazid (HH) 1000 mg once daily despite the resistance status. 
Thus, his current treatment regimen now consists of streptomycin (S) 
750 mg once daily, ethambutol (E) 1200 mg once daily, pyrazinamide 
(Z) 1500 mg once daily, and high dose isoniazid (HH). The patient 
decided to continue his treatment which will last for 20–24 months 
until the resolution of the disease.
The patient blood glucose level was controlled by the administration 
of insulin actrapid and insulatard 8 iu. The patient’s blood glucose was 
monitored 4 times a day: Pre-breakfast, pre-lunch, pre-dinner, and at 
night before sleep (Fig. 1). However, the patient still does not know how 
to administer insulin by himself as this is his 1st time receiving it. The 
patient and caregiver education on this matter was later given to ensure 
that his blood glucose level is controlled, and the ATB medications are 
effective (Table 2).
DISCUSSION
Risk associated with defaulted TB treatment
Many factors such as a drug resistance that obstacles to successful 
directly observed therapy short-course that lead to delay disease 
control. Treatment default is known to be associated with misuse, 
foreign birth, male gender, previous default, low socioeconomic 
status, psychiatric illness, unemployment, migration, side effects, 
long distance to the clinic, social stigma, and poorly-implemented 
therapy short course. Category II cases is classified by the WHO 
for the patients who did not success, default from, or relapse after 
completion of standard first-line TB treatment and present for 
retreatment [6].
A study states that one important risk factor for acquiring MDR-TB 
is a history of previous TB treatment. In this case, the patient had a 
defaulted treatment in 2016. Based on the patient history, DOTS was 
poorly implemented toward this patient. This can be improved by 
counselling and communication between health staff and patients, 
decentralization of treatment involving community health workers, 
flexibility in the choice of DOT supporter, and reinforced supervision 
activities of remote health posts [7].
Managing patient with MDR-TB and DM
Poorly controlled DM increases the risk of MDR-TB, and diabetes leads 
to poor MDR-TB outcomes of treatment. The patient had uncontrolled 
DM since 2016 which can reduce the treatment outcome for ATB 
medications and increase the chance for mortality. Biologically, DM 
affects susceptibility to MDR-TB due to the effects of DM on essential 
and adaptive immunity [8,9]. Minimize ability to clear infection 
could possibly lead to MDR-TB-related deaths among people with 
DM explicitly, and it is also possible that these patients face a greater 
likelihood of death during MDR-TB therapy because of DM associated 
with some concomitant diseases, such as cardiovascular diseases, 
stroke, and renal failure.
Treatment wise, the pharmacokinetics of TB drugs also could be affected 
by disease of DM so that the bactericidal activity is pointed. From the 
patient medication history, rifampicin was administered as a part of 
the first-line ATB regimen. Rifampicin administration could interfere 
with pharmacokinetics of OHA, such as gliclazide, by decreasing its 
level, which in turn impedes glucose control [10]. This interaction may 
contribute to poorer outcome in this patient. This patient will express a 
higher chance of recurrent TB due to reduced immunity that increases 
the susceptibility to reactivation of the earlier infection, which 
manifested a year later in 2017. Patients with hyperglycemia levels had 
significantly reduced levels of rifampicin serum concentrations, thus 
showing an inversely proportional relationship between blood glucose 
and rifampicin serum levels [11]. Hence, the importance of controlling 
blood glucose level cannot be over-emphasized in the presence of TB 
and DM.
During the patient stay in IPR, repeat testing of glucose levels was 
performed 4 times per day. The patient was immediately started 
on insulin on admission to lower his blood glucose level for the ATB 
medications to work efficiently. Administration of insulin for this 
patient was reasonable as there is no interaction between insulin and 
ATB medications.
MDR-TB regimen conversion, adverse drug reactions (ADRs), and 
rechallenge procedure
According to the WHO guideline, patients with RR-TB or MDR-TB 
who were not previously treated with second-line drugs and in whom 
resistance to fluoroquinolones and second-line injectable agents was 
excluded or is considered highly unlikely, a shorter MDR-TB regimen 
of 9–12 months may be used instead of the longer regimens. The 
intensive phase will be 4–6 months while the continuation phase will 
be 5 months. Regimen composition will be 4–6 km-Mfx-Pto-Cfz-Z-
HH-E and 5 Mfx-Cfz-Z-E [4]. Modifications using similar medications 
were made to this patient starting regimen which was Eto and Lfx 
due to unavailability of prothionamide and moxifloxacin. This was 
not a problem as those agents showed equivalent efficacy for treating 
MDR-TB [11,12].
Table 1: Current medication history
Medication 
name
Dose Frequency Route of 
administration
Kanamycin 100 mg OD IM
Clofazimine 750 mg OD PO
Ethionamide 250 mg BD PO
Ethambutol 1200 mg OD PO
Levofloxacin 500 mg OD PO
Pyrazinamide 1500 mg OD PO
Isoniazid 1500 mg OD PO
Insulin Actrapid 8 iu TDS IM
Insulin Insulatard 8 iu OD PO
Table 2: Patient’s demographic and current medication in IPR
Patient details Medication 
Age in years at diagnosis/sex 45/male
Regimens received (time) MDR-TB short regimen











Drugs used for MDR-TB SEZ-HH
Drug resistance H and R
K: Kanamycin, E: Ethambutol, Eto: Ethionamide, Lfx: Levofloxacin, 
Z: Pyrazinamide, HH: High dose isoniazid, Cfz: Clofazimine, S: Streptomycin, 
R: Rifampicin, MDR-TB: Multidrug-resistant tuberculosis, IPR: Institut 
Perubatan Respiratori
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In general, side effects are more serious in second-line treatment 
compared to first-line treatment. In this case, the patient developed 
nausea, vomiting, and urticaria rash a few days after the regimen was 
started. This did not permit further use of the short regimen and require 
changes to long and individualized regimen according to the WHO 2016 
conditional recommendation on selecting a treatment plan for MDR-TB. 
The intensive phase will be up to 8 months and the continuation phase 
will be up to 12 months.
To stop potential offending drugs, TB consultant often rechallenges drug 
one by one from the previous regimen. It is, sometimes, not possible to 
distinguish a reaction as due to the addition of a new drug or due to a 
flare of the underlying reaction. Stopping and starting medications or 
treating with a weak regimen can lead to drug resistance and treatment 
failure, so the balance of preventing harm and providing treatment 
requires significant clinical skill and experience. Most experts would 
not recommend rechallenge once a drug is identified as the causative 
agent.
Lfx and Eto had been identified as the offending agent with Naranjo 
algorithm score of 8 and 6, respectively, representing probable ADR. 
Lfx-induced angioedema cases had been reported in several cases in 
the previous years. Angioedema is defined as sudden swelling of skin, 
subcutaneous and submucosal tissue, and respiratory or gastrointestinal 
tracts which can last up to 7-days. In most cases, discontinuation of the 
drug and administration of antihistamines proved to be effective. Eto 
has a negative inotropic effect on the heart in which its time course 
and intensity correspond to the blood pressure reduction. Treatment is 
mainly supportive. Vital signs should be monitored (sensorium, blood 
pressure, heart, and respiratory rate) regularly, and hypotension must 
be corrected with isotonic fluids or inotropic agents [13].
Inclusion of high-dose isoniazid after isoniazid resistance was 
identified
On discussion with consultant and referring to the WHO guideline, 
isoniazid is recommended alongside a full MDR-TB regimen in patients 
with RR strains confirmed or suspected to be susceptible to isoniazid. 
High-dose isoniazid is one of the core components of the shorter MDR-
TB treatment regimen. Strains bearing mutations in the promoter 
region of the inhA gene may have a minimum inhibitory concentration 
to isoniazid that is low enough to be overcome by high-dose isoniazid. 
In such settings, the drug may still add benefit [4].
Monitoring for potential side effects and ADRs
The patient should be monitored for the risk of hypoglycemia and 
diabetic nephropathy. Changed pharmacokinetic dynamics of ATB 
medications in patients with DM may warrant adjustments in the 
TB treatment regimen. Pyrazinamide and ethambutol doses could 
need to be in sync based on creatinine levels in patients with diabetic 
nephropathy. Pharmacists play important role in ensuring medications 
adherence and providing pharmaceutical care management to TB 
patients with DM [14].
Streptomycin, like other aminoglycosides, possesses the risk of 
nephron- and ototoxicity. Renal function must be monitored by 
documenting creatinine at least monthly. Furthermore, documenting 
baseline and monthly audiology examination is required for audiology 
examinations. Some experts monitor aminoglycoside concentrations 
routinely, regardless of renal function. Pyrazinamide is one of the 
most hepatotoxic ATB agents and the only ATB agents that have the 
potential to cause hyperuricemia in the patient. Therefore, monitoring 
transaminases and uric acid is necessary. For ethambutol, patients 
should be counselled to report any changes in vision. Baseline and 
monthly visual acuity and color discrimination monitoring should be 
performed.
Isoniazid highly necessary needs clinical monitoring for all patients. 
It is recommended to do baseline liver function testing for the 
patients receiving multiple TB drugs or other hepatotoxic drugs or 
with underlying liver disease (including viral hepatitis). Symptoms of 
hepatotoxicity confirmed by follow-up liver function testing. Since this 
patient’s albumin is low, he was predisposed to the risk of hepatotoxicity 
due to the increased concentration of free drugs [15].
CONCLUSION
In summary, the management of MDR-TB can be complicated, 
especially, when the patient cannot tolerate the short regimen. 
Difference in patients’ response and side effects developments toward 
ATB medications requires rechallenging procedure which can have 
prolonged treatment time, hospital stay, and make patients exposed 
to hospital-acquired infection. This challenges and obstacles, however, 
could be prevented earlier by having strong DOTS strategy to prevent 
the development of resistance and reactivation of TB.
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